Lupin is currently trading at Rs. 1510.45, up by 19.80 points or 1.33% from its previous closing of Rs. 1490.65 on the BSE.
The scrip opened at Rs. 1505.00 and has touched a high and low of Rs. 1511.00 and Rs. 1502.50 respectively. So far 1,077 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1511.00 and Rs. 1436.00 respectively. The current market cap of the company is Rs. 68,198.00 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%. Lupin shall commence promoting the product shortly. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% had US sales of $55.7 million, as per IMS MAT Sep 2016.
Lupin’s Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is an AT rated generic equivalent of Mylan Pharmaceuticals, Inc.’s (formerly held by Delcor Asset Corporation) Triamcinolone Acetonide Cream, 0.025% and 0.1%. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.